Browse > Article

Incidence and Prognostic Factors of Radiation Pneumonitis in NSCLC Treated with Intensity Modulated Radiation Therapy(IMRT)  

Kim, Myung-Se (Department of Radiation Oncology, Yeungnam University College of Medicine)
Publication Information
Radiation Oncology Journal / v.26, no.1, 2008 , pp. 35-44 More about this Journal
Abstract
Purpose: To evaluate the incidence and prognostic factors of treatment-related pneumonitis in non-small-cell lung cancer(NSCLC) patients treated with intensity modulated radiation therapy(IMRT). Materials and Methods: One-hundred-five patients with NSCLC treated with IMRT between 1 August 2004 and 30 November 2006 were analyzed retrospectively. The mean age of patients was 62.9 years, and squamous carcinomas were confirmed in 81 patients(77%). Sixty-six patients(62.9%) were classified as stage III, and 59 patients had lesions in the right lung. Twenty-seven patients were treated with a dose of 3,060 cGy preoperatively, and 10 patients were given a dose of 5,040 cGy postoperatively. Sixty-eight patients received a dose of 7,020 cGy for curative intent. Sixty-eight patients were treated with the use of the CORVUS planning system and 37 patients were treated with the use of the ECLIPSE planning system. Results: Of 105 patients, 21 patients(20%) had abnormal radiological findings, but only seven patients(6.7%) required treatment for radiation pneumonitis. Six of the seven patients had other serious lesions, including a bronchioesophageal fistula(one patient), recurrence in the treatment field(two patients), brain metastasis(one patient) and lung-to-lung metastasis(two patients); all of these patients died within 19 months after radiation treatment. Sixteen patients(23.5%) that received planning with the CORVUS system had abnormal lung findings. Five patients(13.5%) had abnormal lung findings with the use of the ECLIPSE planning system. Other prognostic factors such as perioperative radiation therapy, a volume over 10% of the V20 volume in the right lung, were also statistically significant. Conclusion: This retrospective analysis suggests that IMRT could be a beneficial treatment modality for the reduction of radiation pneumonitis in NSCLC patients. However, the higher incidence of abnormal radiological findings in perioperative patients treated with relatively lower doses($3,060{\sim}5,040$ cGy) suggest the need for judicious treatment planning in preoperative or postoperative treatment.
Keywords
Intensity modulated radiation therapy(IMRT); Non-small-cell lung cancer(NSCLC); Radiation pneumonitis; Incidence rate; Prognostic factors;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Travis EL, Komaki R. Treatment-related lung cancer. In: Pass HI, Carbone DP, Minna JD, Johnson DH, Turrisi AT III. Lung Cancer. Principles and Practice. 3rd ed. Philadelphia, Baltimore, NY, London, Hong Kong, Sydney, Tokyo: Lippincott Williams & Wilkins. 2005:545-567
2 Beckmann GK, Kolbl O, Krieger T, Wulf J, Flentje MP. How can we further improve radiotherapy for stage-III non-small-cell lung cancer? Lung cancer 2004;45S:125-132
3 Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;60:741-747   DOI   ScienceOn
4 Liu HH, Wang CW, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1268-1279   DOI   ScienceOn
5 Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;66:1595-1596   PUBMED
6 Bradley JD, Hope A, Naqa IE, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 2007;69:985-992   DOI   ScienceOn
7 Miles EF, Kelsey CR, Kirkpatrick JP, Marks LB. Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for non-small-cell lung cancer: Calculations from clinical trials. Int J Radiat Oncol Biol Phys 2007;68:1047-1052   DOI   PUBMED   ScienceOn
8 Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005;63:5-24   DOI   ScienceOn
9 Sekine I, Sumi M, Ito Y, et al. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol 2006;80:93-97   DOI   ScienceOn
10 Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phy 2007;69:350-357   DOI   ScienceOn
11 Kimura T, Matsuura K, Murakami Y, et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys 2006;66:483-491   DOI   ScienceOn
12 Huang EH, Liao Z, Cox JD, et al. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 2007;68:779-785   DOI   ScienceOn
13 Dong L, Mohan R. Intensity-modulated radiation therapy, physics and quality assurance. In: Chao KSC, Apisarnthanarax S, Ozigit G. Practical Essentials of Intensity Modulated Radiation Therapy. 2nd ed. Philadelphia, Baltimore, NY, London, Hongkong, Sydney, Tokyo: Lippincott Williams & Wilkins. 2005:2-19
14 Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 2006;66:1281-1293   DOI   ScienceOn
15 Onn A, Vaporciyan AA, Chang JY, Komaki R, Roth JA, Herbst RS. Cancer of the lung. In: Kufe DW, Bast RC, Hait WN, et al. Cancer Medicine. 7th ed. Hamilton, London: BC Decker Inc. 2006:1179-1224
16 Grills IS, Yan DY, Martinez AA, Vicini FA, Wong JW, Kestine LL. Potential for reduced toxicity and dose escalation in the treatment of imoperable non-small cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT) 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003;57:875-890   DOI   ScienceOn
17 Seibert RM, Ramsey CR, Hines JW, et al. A model for predicting lung cancer response to therapy. Int J Radiat Oncol Biol Phys 2007;67:601-609   DOI   ScienceOn
18 Belderbos JSA, Heemsbergen WD, Jaeger KD, Baas P, Lebesque JV. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:126-134   DOI   ScienceOn
19 Wall RJ, Schnapp LM. Radiation pneumonitis. Respiratory Care 2006;51:1255-1260   PUBMED
20 Rojas AM, Lyn BE, Wilson EM, et al. Toxicity and outcome of a phase II trial of Taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Cancer 2006;107:1321-1330   DOI   ScienceOn
21 Choi Y, Lee HS, Hur WJ, et al. Impact of intensity modulated radiation therapy as a boost treatment on the lung dose distributions for non-small-cell lung cancer. Lung Cancer 2005;4:6-14
22 Boyer AL. Intensity modulated radiation therapy. In: Khan FM. Treatment Planning in Radiation Oncology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2007:142-165
23 Hope AJ, Linsay PE, Naqa IE, et al. Modeling radiation pneumonitis risk with clinical, dosimetric and spatial parameters. Int J Radiat Oncol Biol Phys 2006;65:112-124   DOI   ScienceOn
24 Wagner H Jr. Non-small-cell lung cancer. In: Gunderson LL, Tepper JE. Clinical Radiation Oncology. 2nd ed. Churchhill: Livingstone. 2007:911
25 Weiss E, Ramakrishnan V, Keall PJ. Is there a selection bias in radiotherapy dose-escalation protocols? Int J Radiat Oncol Biol Phys 2007;68:1359-1365   DOI   ScienceOn
26 Baisden JM, Romney DA, Reish AG, et al. Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors. Int J Radiat Oncol Biol Phys 2007;68:1229-1237   DOI   ScienceOn
27 Wu KL, Jiang GL, Liao Y, et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 2003;57:2336-1344
28 Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherpay for advanced-stage non-small-cell lung cancer. Int J Radiat Onol Biol Phys 2004;58:1258-1267   DOI   ScienceOn
29 Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and tree-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006;66:1399-1407   DOI   ScienceOn
30 Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI. Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 2007;67:410-416   DOI   ScienceOn
31 Giraud P, De Rycke Y, Lavole A, Milleron B, Cosset J-M, Rosenzweig KE. Probability of mediastinal involvement in non-small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy? Int J Radiat Oncol Biol Phys 2006;64:127-135   DOI   ScienceOn